ImmunityBio (IBRX) Common Equity (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Common Equity of -$870.0 million for Q1 2026, down 47.34% year-over-year from -$1.7 billion in Q1 2025, and down 73.84% quarter-over-quarter from -$500.5 million in Q4 2025.
ImmunityBio (IBRX) Common Equity (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Common Equity for 13 consecutive years, with -$870.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 47.34% year-over-year to -$870.0 million; the TTM figure through Mar 2026 stood at -$870.0 million (down 47.34% YoY), while the FY2025 annual figure was -$500.5 million, down 2.53% from the prior year.
- Common Equity fell to -$870.0 million in Q1 2026 per IBRX's latest filing, from -$500.5 million in the prior quarter.
- Across five years, Common Equity topped out at $100000.0 in Q3 2024 and bottomed at -$870.0 million in Q1 2026.
- Historically, Common Equity has averaged -$514.3 million across 5 years, with a median of -$524.3 million in 2025.
- Annual changes were most pronounced in 2024 — Common Equity surged 100.02% — and 2025, when it sank 524419.0%.
- ImmunityBio's Common Equity stood at -$449.8 million in 2022, then sank by 30.26% to -$585.9 million in 2023, then increased by 16.69% to -$488.1 million in 2024, then fell by 2.53% to -$500.5 million in 2025, then tumbled by 73.84% to -$870.0 million in 2026.
- Business Quant data shows IBRX's Common Equity at -$870.0 million in Q1 2026, -$500.5 million in Q4 2025, and -$524.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | -1.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.05 Bn |
| Mar 31, 2026 | -870.01 Mn |
| Dec 31, 2025 | -500.47 Mn |
| Sep 30, 2025 | -524.32 Mn |
| Jun 30, 2025 | -569.82 Mn |
| Mar 31, 2025 | -590.48 Mn |
| Dec 31, 2024 | -488.13 Mn |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | -697.38 Mn |
| Mar 31, 2024 | -690.98 Mn |
| Dec 31, 2023 | -585.94 Mn |
| Sep 30, 2023 | -410.65 Mn |
| Jun 30, 2023 | -645.18 Mn |
| Mar 31, 2023 | -531.72 Mn |
| Dec 31, 2022 | -449.82 Mn |
| Sep 30, 2022 | -429.08 Mn |
| Jun 30, 2022 | -421.97 Mn |
| Mar 31, 2022 | -337.56 Mn |
| Dec 31, 2021 | -243.91 Mn |
| Sep 30, 2021 | -189.94 Mn |